Answers are grounded in this paper and cite their sources.
Analysis shows high SARC-F score predicts chemotherapy discontinuation in colorectal cancer patients, suggesting potential for improved outcomes.
Background and Objectives Sarcopenia adversely affects clinical outcomes in patients with cancer. Studies indicate that sarcopenia significantly predicts chemotherapy‐induced dose‐limiting toxicities, including early discontinuation, delay, and dose‐reduction, in patients with colorectal, esophageal, digestive, hepatocellular, and renal cancers. The Strength, Assistance for walking, Rising from a chair, Climbing stairs, and Falls (SARC‐F) questionnaire is a simple and effective tool for sarcopenia screening. Adjuvant chemotherapy is the standard treatment for advanced (Stages II/III) colorectal cancer (CRC). Predicting chemotherapy discontinuation could help improve oncologic outcomes. This study aimed to evaluate the correlation between the SARC‐F score and chemotherapy discontinuation. Methods This study included 139 patients with CRC who underwent surgery between July 2016 and June 2023, received adjuvant chemotherapy and completed the SARC‐F questionnaire before surgery. The SARC‐F includes five items, each scored from 0 to 2. Patients were divided into two groups based on optimal SARC‐F cutoff value. Treatment discontinuation was analyzed using a logistic regression model. Results Patients were categorized into high‐SARC‐F ( n = 18) and low‐SARC‐F ( n = 121) groups. Patients in the high‐SARC‐F group were older ( p < 0.001), had higher rates of hypertension ( p = 0.001) and diabetes mellitus ( p = 0.017), elevated preoperative C‐reactive protein levels ( p < 0.001), and a higher incidence of treatment discontinuation ( p = 0.010). Univariate and multivariate analyses identified a high SARC‐F score as an independent risk factor for chemotherapy discontinuation (odds ratio 3.905, 95% confidence interval 1.100–13.867). Conclusions Our findings indicate that the SARC‐F score reflects sarcopenia characteristics and can predict adjuvant chemotherapy discontinuation in patients with CRC.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: